Pages that link to "Q33777476"
Jump to navigation
Jump to search
The following pages link to Ipilimumab and its toxicities: a multidisciplinary approach (Q33777476):
Displaying 50 items.
- Toxicity management of immunotherapy for patients with metastatic melanoma (Q26738662) (← links)
- Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities (Q26775383) (← links)
- Immune Checkpoint Blockade: A New Paradigm in Treating Advanced Cancer (Q26795509) (← links)
- Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer (Q26853171) (← links)
- Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience (Q26995499) (← links)
- Toxicities of Immunotherapy for the Practitioner (Q27008140) (← links)
- Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy (Q27021570) (← links)
- The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment (Q27022789) (← links)
- Aptamers: A New Technological Platform in Cancer Immunotherapy (Q28068981) (← links)
- Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond (Q28077815) (← links)
- Prospects of immune checkpoint modulators in the treatment of glioblastoma (Q28081371) (← links)
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination (Q30251438) (← links)
- Extracutaneous melanomas: a primer for the radiologist (Q30397680) (← links)
- Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma (Q33591598) (← links)
- Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer (Q33623877) (← links)
- Melanoma: more answers, more questions (Q33777422) (← links)
- Current concepts in the diagnosis and management of cytokine release syndrome (Q33886879) (← links)
- Cancer immunotherapy in clinical practice -- the past, present, and future. (Q34309399) (← links)
- Dextran as a generally applicable multivalent scaffold for improving immunoglobulin-binding affinities of peptide and peptidomimetic ligands. (Q34431415) (← links)
- Nivolumab in NSCLC: latest evidence and clinical potential (Q34466452) (← links)
- PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective (Q34550012) (← links)
- PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma (Q34667977) (← links)
- Immune modulation for cancer therapy (Q34686944) (← links)
- Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice (Q35064059) (← links)
- Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma. (Q36173638) (← links)
- Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice (Q36871188) (← links)
- Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors (Q37265479) (← links)
- Evaluation of immune infiltration in the colonic mucosa of patients with ipilimumab-related colitis (Q37308199) (← links)
- Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". (Q37670024) (← links)
- Exploring the potential of immuno-oncology-based treatment for patients with non-small cell lung cancer (Q38246950) (← links)
- Translational research in oncology--10 years of progress and future prospects (Q38257126) (← links)
- Clinical impact of checkpoint inhibitors as novel cancer therapies (Q38262593) (← links)
- Immune-based therapies for childhood cancer. (Q38263108) (← links)
- Iatrogenic pathology of the intestines. (Q38339456) (← links)
- Management of pulmonary toxicity associated with targeted anticancer therapies (Q38570532) (← links)
- Interleukin-2, Ipilimumab, and Anti-PD-1: Clinical Management and the Evolving Role of Immunotherapy for the Treatment of Patients With Metastatic Melanoma (Q38595251) (← links)
- Immune checkpoint inhibitors: a new frontier in bladder cancer (Q38612706) (← links)
- Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy (Q38615337) (← links)
- New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. (Q38632728) (← links)
- Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies (Q38636711) (← links)
- Combination cancer immunotherapies tailored to the tumour microenvironment (Q38645178) (← links)
- Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data (Q38648615) (← links)
- Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies (Q38670099) (← links)
- Treatment of Ipilimumab Induced Graves' Disease in a Patient with Metastatic Melanoma. (Q38735236) (← links)
- Checkpoint inhibition and melanoma: Considerations in treating the older adult (Q38785125) (← links)
- Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma (Q38831217) (← links)
- Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer (Q38856570) (← links)
- Ipilimumab in melanoma (Q38893697) (← links)
- Intralesional and systemic immunotherapy for metastatic melanoma (Q38948218) (← links)
- Acute management of autoimmune toxicity in cancer patients on immunotherapy: Common toxicities and the approach for the emergency physician (Q39091517) (← links)